Citius Oncology, Inc. (CTOR) Stock Analysis & Investment Frameworks
Citius Oncology, Inc. (CTOR) stock analysis on Invetso. Review Citius Oncology, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Citius Oncology, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
Citius Oncology, Inc. Key Financial Metrics
- Market Cap: $47.37M
- Revenue: $N/A
- ROE: -102.98%
- ROIC: -88.72%
- Dividend Yield: N/A
About Citius Oncology, Inc.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Citius Oncology, Inc. Investment Frameworks
Invetso analyzes Citius Oncology, Inc. (CTOR) across the following frameworks:
- Citius Oncology, Inc. 10Y Growth Potential
- Citius Oncology, Inc. Scenario Analysis
- Citius Oncology, Inc. Risks & Opportunities
- Citius Oncology, Inc. Economic Moat
- Citius Oncology, Inc. Business Model
- Citius Oncology, Inc. Management
- Citius Oncology, Inc. SWOT Analysis
- Citius Oncology, Inc. Porter's 5 Forces
- Citius Oncology, Inc. PESTLE Analysis
- Citius Oncology, Inc. ESG Analysis